MDT-AP-2172
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 36.839999999999996
- os_event
- true
- age_years
- 4.5
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.218008801
- umap2_2d
- -0.123026447
- umap1_3d
- -0.577265294
- umap2_3d
- -1.569759732
- umap3_3d
- 0.053520602
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.470
- ANGIOGENESIS+0.390
- TNFA_SIGNALING_VIA_NFKB+0.390
- ALLOGRAFT_REJECTION+0.380
- INFLAMMATORY_RESPONSE+0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- IL6_JAK_STAT3_SIGNALING+0.370
- PANCREAS_BETA_CELLS+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- KRAS_SIGNALING_UP+0.290
Top 10 suppressed
- MITOTIC_SPINDLE-0.380
- PI3K_AKT_MTOR_SIGNALING-0.290
- HEDGEHOG_SIGNALING-0.240
- G2M_CHECKPOINT-0.220
- E2F_TARGETS-0.190
- APICAL_JUNCTION-0.140
- XENOBIOTIC_METABOLISM-0.130
- HEME_METABOLISM-0.120
- PEROXISOME-0.120
- UV_RESPONSE_DN-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2510 | Med | Medulloblastoma | 0.840 |
| 2 | 88652d2f-b913-41e8-bd7c-c40967e94d5f | — | — | 0.823 |
| 3 | MDT-AP-2183 | Med | Medulloblastoma | 0.806 |
| 4 | TCGA-D8-A1Y2-01A-11R-A157-07 | — | C | 0.793 |
| 5 | TCGA-60-2720-01A-01R-0851-07 | — | cohortSQ1 | 0.792 |
| 6 | SRR1313163 | — | D | 0.791 |
| 7 | MDT-AP-2506 | Med | Medulloblastoma | 0.782 |
| 8 | MDT-AP-2377 | Med | Medulloblastoma | 0.781 |
| 9 | TCGA-64-1676-01A-01R-0946-07 | — | cohortA1 | 0.780 |
| 10 | TCGA-18-3406-01A-01R-0980-07 | — | cohortSQ1 | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.160 | Inavolisib | — uncovered |